Investors watch RNA therapy companies for signs of future profits

Only a few weeks ago, there was talk of a biotech stock slump, but now some of those same companies are in vogue again, at least in the popular press. Those that make RNA-based therapies are beginning to win over skeptics who are impatiently waiting for commercialization; doubts will remain until they produce a profitable product. Story

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.